Law EH, Galve-Calvo E, Wockel A, Parikh R, Kurosky SK, Derrien Ansquer V, Frugier G, Davis KL, Esterberg E, Oikonomidou O. European treatment patterns and outcomes associated with first-line CDK4/6 inhibition and hormonal therapies assessed in a real-world non-interventional study (EUCHARIS). Poster presented at the 2021 San Antonio Breast Cancer Symposium (SABCS); December 7, 2021. San Antonio, TX. [abstract] Cancer Res. 2022 Feb 15; 82(4_Suppl):OT2-19-04. doi: 10.1158/1538-7445.SABCS21-OT2-19-04
Parikh R, Kurosky SK, Udall M, Chang J, Cappelleri JC, Doherty JP, Kaye JA. Treatment patterns and health outcomes in platinum-refractory or platinum-resistant ovarian cancer: a retrospective medical record review. Int J Gynecol Cancer. 2018 May;20(4):738-48. doi: 10.1097/IGC.0000000000001222
Dine JL, Garimella SV, Gehlhaus K, Grandin M, Letwin D, Caplen N, Lipkowitz S. Gp78 is a negative regulator of TRAIL-induced apoptosis in breast cancer cells. Poster presented at the 106th Annual Meeting of the American Association for Cancer Research; April 2015. Philadelphia, PA. [abstract] Cancer Res. 2015 Aug; 75(15 Suppl):15. doi: 10.1158/1538-7445.AM2015-15
Hansen MK, Gammelager H, Jacobsen CJ, Hjortdal VE, Layton JB, Rasmussen BS, Andreasen JJ, Johnsen SP, Christiansen CF. Acute kidney injury and long-term risk of cardiovascular events after cardiac surgery: a population-based cohort study. J Cardiothorac Vasc Anesth. 2015 Jun;29(3):617-25. doi: 10.1053/j.jvca.2014.08.020
Sherrill B, Amonkar MM, Sherif BN, Maltzman J, O'Rourke L, Johnston S. An exploration of the association of Quality-of-Life (QOL) scores with tumor progression status in first line hormone receptor positive, HER2+ Metastatic Breast Cancer (MBC) patients treated with lapatinib plus letrozole or letrozole alone. Poster presented at the Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 2009. San Antonio, TX. [abstract] Cancer Res. 2009 Dec; 69(24 (Suppl)):5106. doi: 10.1158/0008-5472.SABCS-09-5106
Alverez SA, Bae-Jump V, Havrilesky LJ, Calingaert B, Clarke-Pearson ADL, Soper JT, Gehrig PA. Attitudes regarding the use of hematopoietic colony-stimulating factor utilization and maintenance of relative dose intensity among gynecologic oncologists. Int J Gynecol Cancer. 2009 Apr;19(3):447-54.
Schildkraut JM, Goode EL, Clyde MA, Iversen ES, Moorman PG, Berchuck A, Marks JR, Lissowska J, Brinton L, Peplonska B, Cunningham JM, Vierkant RA, Rider DN, Chenevix-Trench G, Webb PM, Beesley J, Chen X, Phelan C, Sutphen R, Sellers TA, Pearce L, Wu AH, Den Berg DV, Conti D, Elund CK, Anderson R, Goodman MT, Lurie G, Carney ME, Thompson PJ, Gayther SA, Ramus SJ, Jacobs I, Kjaer SK, Hogdall E, Blaakaer J, Hogdall C, Easton DF, Song H, Pharoah HDP, Whittemore AS, McGuire V, Quaye L, Anton-Culver H, Ziogas A, Terry KL, Cramer DW, Hankinson SE, Tworoger SS, Calingaert B, Chanock S, Sherman M, Garcia-Closas M. Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res. 2009 Mar;69(6):2349-57.
Lancaster JM, Sayer RA, Blanchette C, Calingaert B, Konidari I, Gray J, Schildkraut J, Schomberg DW, Marks JR, Berchuck A. High expression of insulin-like growth factor binding protein–2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int J Gynecol Cancer. 2006 Jul 1;16(4):1529-35.
Wood CE, Register TC, Franke AA, Anthony MS, Cline JM. Dietary soy isoflavones inhibit estrogen effects in the postmenopausal breast. Cancer Res. 2006 Jan 15;66(2):1241-9.
Paramastri YA, Anthony MS, Wilkinson LM, Phifer BM, Cline JM. Dietary soy phytoestrogens inhibit tumor promotion by exogenous but not endogenous estrogens in the rat DMBA model of mammary carcinogenesis. Cancer Res. 2001 Mar;42(Suppl):310.
Suit HD, Sedlacek R, Wagner M, Orsi L, Silobrcic V, Rothman KJ. Effect of corynebacterium parvum on the response to irradiation of a c3h fibrosarcoma. Cancer Res. 1976 Apr 1;36(4):1305-14.